PR Newswire
TORRANCE, Calif., April 26, 2022
TORRANCE, Calif., April 26, 2022 /PRNewswire/ -- Emmaus Life Sciences, Inc. (OTCQX: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today announced participation in the following investor conferences in May:
Emmaus' management team will be available for one-on-one meetings during both conferences. To schedule a one-on-one meeting, please contact your respective conference representative or Michael Miller with Rx Communications at [email protected].
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com.
Company Contact:
Emmaus Life Sciences, Inc.
Willis Lee
Chief Operating Officer
(310) 214-0065 x1130
[email protected]
Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/emmaus-life-sciences-to-present-at-investor-conferences-in-may-301532914.html
SOURCE Emmaus Life Sciences, Inc.
We use cookies to tailor your experience, measure site performance and present relevant offers and advertisements. By clicking ‘Accept’ or any content on this site, you agree that cookies can be placed on your browser. You can view our privacy policy to learn more.
If you would like to get more data, alerts and access to Real Vision videos, join us as an Insider Tracking Advantage Ultra member